ArticleNature2020
Action of a minimal contractile bactericidal nanomachine.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
12.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 124 citations in OpenAlex.
- A programmable DNA origami nanosyringe for directed membrane translocation.Nature nanotechnology · 2026Article
- Article
- F-Type Pyocin Versus Phage λ Tail: Conserved Hub, Divergent Fibers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Intact architectures of myophage phi92 in extended and contracted states.PLoS pathogens · 2026Article
- Conformational changes of the baseplate regulating tail contraction of Staphylococcus phage 812.The EMBO journal · 2026Article
- Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives.MedComm · 2026Review
- Review
- Targeted delivery of diverse biomolecules with engineered bacterial nanosyringes.Nature biotechnology · 2026Article
- A phage-derived reconfigurable effector associated with an actinobacterial contractile nanomachine tailors bacterial responses to competition.Journal of bacteriology · 2026Article
- Synergistic Bactericidal Effects of R- and F-Type Pyocin Cocktails Against ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection.Communications biology · 2026Article
- Stepwise firing mechanism of an extracellular contractile injection system.Nature communications · 2026Article
- Lipopolysaccharide-targeting treatments for multidrug-resistantExpert opinion on therapeutic targets · 2026Review
- Efagins - engineerable agents that evolved independently to target the enterococcal cell wall.bioRxiv : the preprint server for biology · 2026Article
- A dramatic protein fold switch powers a bactericidal nanomachine.bioRxiv : the preprint server for biology · 2026Article
- Genomic diversification and tailocin-mediated competition in animal-associatedISME communications · 2026Article
- Structure of defense against restriction proteins DarA and Hdf in phage P1 reveals a new molecular mechanism during phage assembly, infection and DNA ejection.PLoS pathogens · 2026Article
- Structural atlas ofbioRxiv : the preprint server for biology · 2025Article
- Genomic correlates of tailocin sensitivity in Pseudomonas syringae.G3 (Bethesda, Md.) · 2025Article
- Structural characterization of an extracellular contractile injection system from Photorhabdus luminescens in extended and contracted states.Nature communications · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 3 countries.
Peng Ge *Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2661-8226
Dean Scholl *Pylum Biosciences, South San Francisco, CA, USA.
Nikolai S ProkhorovUniversity of Texas Medical Branch, Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, Galveston, TX, USA.ORCID http://orcid.org/0000-0001-9621-0245
Jaycob AvaylonThe California NanoSystems Institute (CNSI), University of California, Los Angeles (UCLA), Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-8360-9409
Mikhail M ShneiderShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Laboratory of Molecular Bioengineering, Moscow, Russia.ORCID http://orcid.org/0000-0002-3768-3541
Christopher BrowningVertex Pharmaceuticals (Europe) Ltd, Abingdon, UK.
Sergey A ButhUniversity of Texas Medical Branch, Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, Galveston, TX, USA.ORCID http://orcid.org/0000-0003-1922-0866
Michel PlattnerUniversity of Texas Medical Branch, Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, Galveston, TX, USA.
Urmi ChakrabortyPylum Biosciences, South San Francisco, CA, USA.
Ke DingDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-0115-5931
Petr G LeimanUniversity of Texas Medical Branch, Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, Galveston, TX, USA.ORCID http://orcid.org/0000-0002-9091-0918
Jeff F MillerDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA, USA. jfmiller@UCLA.edu.
Z Hong ZhouDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA, USA. Hong.Zhou@UCLA.edu.ORCID http://orcid.org/0000-0002-8373-4717
California NanoSystems Institute · USThe University of Texas Medical Branch at Galveston · USInstitute of Bioorganic Chemistry · RUVertex Pharmaceuticals (United Kingdom) · GB
Funding
High-Resolution CryoEM Reconstruction of Large ComplexesR01GM071940 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ZHOU, Z HONG · 2006 to 2025
$5.0MWest/Midwest Consortium for High-Resolution Cryo Electron MicroscopyU24GM116792 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGBANDJE-MCKENNA, MAVIS, DOKLAND, TERJE · 2016 to 2020
$3.0MTitle: Development of Modified R-type Bacteriocins to Specifically Target C. difficileand Prevent Relapse of CDIs.R33AI121692 · NIAID · PYLUM BIOSCIENCES, INC. · PI SCHOLL, DEAN M · 2018 to 2020
$1.5MDirect Detection Device for atomic resolution cryoEM of macromolecular complexesS10OD018111 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHOU, Z HONG · 2014 to 2014
$598kGenerating a library of antimicrobial R-type pyocins against enteric bacteriaR21AI085318 · NIAID · AVIDBIOTICS CORPORATION · PI SCHOLL, DEAN M · 2010 to 2011
$373kAmerican Heart Association-American Stroke AssociationNIAID NIH HHS R21 AI085318NIAID NIH HHS R33 AI121692NIGMS NIH HHS R01 GM071940NIGMS NIH HHS U24 GM116792NIH HHS S10 OD018111
Abstract
R-type bacteriocins are minimal contractile nanomachines that hold promise as precision antibiotics
Indexed as
Pseudomonas aeruginosaBacteriophage T4Cryoelectron MicroscopyCrystallography, X-RayGenes, BacterialModels, MolecularProtein SubunitsPyocinsSubstrate SpecificityType VI Secretion SystemsProtein SubunitsPyocinsType VI Secretion Systems
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.